Highest-materiality recent filing
IMAC acknowledges default under senior secured notes and transfers 100% of Ignite Proteomics equity and related assets to collateral agent.
IMAC Holdings issues $210K secured promissory note at $150K purchase price
Note principal $210,000; proceeds $150,000; effective discount $60,000.
IMAC Holdings issues $222,600 secured promissory note at $159,000 purchase price, due Jan 31, 2026
Issued secured promissory note on Jan 29, 2026 for aggregate principal $222,600; purchase price $159,000.
IMAC Holdings issues $7.53M senior secured notes due Jan 31, 2026
Aggregate principal $7,530,929.74; purchase price ~$6,332,901.16 via cash and debt conversion.
IMAC Holdings issues $247,800 secured note at $177,000; matures Feb 13, 2026
Aggregate principal amount of $247,800; net proceeds of $177,000 (original issue discount of $70,800).
IMAC Holdings issues $179K unsecured note at $128K net; director Pruitt resigns
Issued unsecured promissory note for $179,375 principal, net proceeds $128,125, maturing Dec 24, 2025.
Ignite Proteomics (BACK) enters $420K biomarker study with Inova for GI cancers
Subsidiary Ignite Proteomics will analyze up to 600 tumor samples using RPPA technology.
IMAC Holdings issues $128,800 promissory note at $92,000 purchase price, matures Dec 2025
Principal amount $128,800; purchased for $92,000 (implied discount of $36,800).
IMAC Holdings restates FY2024 and two Q 2024 financials over preferred dividend error
Audit Committee on May 16, 2025 determined Q2 and Q3 2024 and FY 2024 financials unreliable due to non-cash preferred dividend accounting error.
IMAC Holdings dismisses Marcum, hires CBIZ CPAs as auditor effective May 2, 2025
Marcum dismissed April 30, 2025; CBIZ CPAs engaged May 2, 2025 for fiscal 2025.
On March 24, received Nasdaq suspension/delisting notice for March 26; now trading OTC Pink.
Nasdaq denies IMAC Holdings' appeal; stock to be suspended March 26, delisted
Nasdaq Hearings Panel denied IMAC's request to continue listing; trading suspended at open March 26, 2025.
Nasdaq notified IMAC its stock failed to meet $1.00 minimum bid price for 30 consecutive days; compliance period until Sept 9, 2025.
Issued $150,500 principal promissory notes for $107,500; unsecured, mature upon $1M offering or Nov 18, 2025.
IMAC Holdings faces Nasdaq delisting; seeks shareholder approval for large stock issuances
Filed proxy for March 26 special meeting to approve issuing >19.99% of common stock under Series G Preferred and equity financing.
IMAC Holdings receives Nasdaq delisting notice; intends to appeal by Jan 28
On Jan 21, 2025, Nasdaq notified IMAC it fails minimum stockholders' equity requirement ($2.5M) under Listing Rule 5550(b)(1).
IMAC Holdings closes $3.74M PIPE, enters $60M equity line, amends preferred stock terms
Raised $3.74M via PIPE of Series G Preferred Stock (convertible at $1.57) and warrants (exercise price $1.44).
IMAC Holdings receives Nasdaq deficiency notices for audit committee vacancy and delayed 10-Q filing
Audit Committee Notice on Nov 21, 2024: vacancy from Cary Sucoff's resignation (Sep 9, 2024) violates Nasdaq Listing Rule 5605.
On June 2, 2025, IMAC Holdings, Inc. (the “Company”) appointed Jason Lobel and Saundra Pelletier as a member of the Board of Directors of the Company.
On June 2, 2025, IMAC Holdings, Inc. (the “Company”) appointed Jason Lobel and Saundra Pelletier as a member of the Board of Directors of the Company.
On May 30, 2025, Jeffrey Busch notified the Board of Directors (the “Board”) of IMAC Holdings, Inc. (the “Company”) of his resignation as director, effective on May 31, 2025.
On September 19, 2024, IMAC Holdings, Inc. (the “Company”) appointed Jeffrey Busch as a member of the Board of Directors of the Company.
On September 6, 2024, Cary Sucoff notified the Board of Directors (the “Board”) of IMAC Holdings, Inc. (the “Company”) of his resignation as director, effective on September 9, 2024.
Peter Beitsch, MD, and Matthew Schwartz, MD joined the Board, effective June 26, 2024.
Peter Beitsch, MD, and Matthew Schwartz, MD joined the Board, effective June 26, 2024.
Also on May 23, 2024, Jeffrey S. Ervin notified the Board of his resignation as Chief Executive Officer and director, effective immediately.
On May 23, 2024, the Company appointed Faith Zaslavsky as Chief Executive Officer of the Company, effective immediately.
On May 23, 2024, Matthew C. Wallis, DC, notified the Board of Directors (the “Board”) of IMAC Holdings, Inc. (the “Company”) of his resignation as director, effective immediately.
On November 24, 2023, Matthew C. Wallis, DC notified the Company of his resignation as the Company’s President, effective as of that date.
On February 28, 2023, Dr. Ben Lerner notified the Company of his resignation as the Company’s Chief Operating Officer to pursue other interests, effective as of February 28, 2023.
Max materiality 0.95 · Median 0.50 · Most common event debt